CANbridge Pharmaceuticals Inc.

Patients with glioblastoma can expect to live a median eight months after diagnosis, but two anticipated launches in 2024 and a rich development pipeline could improve that bleak clinical outlook. “Th

China's National Medical Products Administration (NMPA) has issued approvals for two drugs that will help pediatric patients with rare conditions. AstraZeneca PLC has obtained a green light for its

Chinese biotech doing US-China cross-border deals have long used Silicon Valley Bank as the go-to bank for such transactions. Mostly due to China’s strict control over foreign currency flow. Many biot

Located strategically in US innovation hubs, meanwhile stationing most of their development and regulatory personnel in central cities in China, dual-headquartered China-US biotechs have been riding h